
Stephen T Abedon

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1988838/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Prophages Preventing Phage Superinfection. , 2022, , 179-191.		1
2	Transduction of Large Amounts of DNA. , 2022, , 137-150.		1
3	Bacteriophages as Drivers of Evolution. , 2022, , .		6
4	Phage Morons. , 2022, , 153-164.		1
5	Pathways to Phage Therapy Enlightenment, or Why I Have Become a Scientific Curmudgeon. Phage, 2022, 3, 95-97.	0.8	5
6	Further Considerations on How to Improve Phage Therapy Experimentation, Practice, and Reporting: Pharmacodynamics Perspectives. Phage, 2022, 3, 98-111.	0.8	6
7	Phage Therapy: The Pharmacology of Antibacterial Viruses. Current Issues in Molecular Biology, 2021, 40, 81-164.	1.0	40
8	Bacteriophage Pharmacology and Immunology. , 2021, , 295-339.		3
9	Virus-Like Particle: Evolving Meanings in Different Disciplines. Phage, 2021, 2, 11-15.	0.8	6
10	Improving Phage-Biofilm In Vitro Experimentation. Viruses, 2021, 13, 1175.	1.5	19
11	Bacteriophage Ecology. , 2021, , 253-294.		9
12	Detection of Bacteriophages: Phage Plaques. , 2021, , 507-538.		9
13	Phage Cocktail Development for Bacteriophage Therapy: Toward Improving Spectrum of Activity Breadth and Depth. Pharmaceuticals, 2021, 14, 1019.	1.7	72
14	Phage Therapy in the 21st Century: Is There Modern, Clinical Evidence of Phage-Mediated Efficacy?. Pharmaceuticals, 2021, 14, 1157.	1.7	32
15	Friends or Foes? Rapid Determination of Dissimilar Colistin and Ciprofloxacin Antagonism of Pseudomonas aeruginosa Phages. Pharmaceuticals, 2021, 14, 1162.	1.7	15
16	Treating Bacterial Infections with Bacteriophage-Based Enzybiotics: In Vitro, In Vivo and Clinical Application. Antibiotics, 2021, 10, 1497.	1.5	44
17	Coming-of-Age Characterization of Soil Viruses: A User's Guide to Virus Isolation, Detection within Metagenomes, and Viromics. Soil Systems, 2020, 4, 23.	1.0	61

18 Phage-Phage, Phage-Bacteria, and Phage-Environment Communication., 2020, , 23-70.

7

STEPHEN T ABEDON

#	Article	IF	CITATIONS
19	Bacteriophage Ecology. , 2020, , 1-42.		4
20	Use of phage therapy to treat long-standing, persistent, or chronic bacterial infections. Advanced Drug Delivery Reviews, 2019, 145, 18-39.	6.6	57
21	Look Who's Talking: T-Even Phage Lysis Inhibition, the Granddaddy of Virus-Virus Intercellular Communication Research. Viruses, 2019, 11, 951.	1.5	52
22	Phage-Antibiotic Combination Treatments: Antagonistic Impacts of Antibiotics on the Pharmacodynamics of Phage Therapy?. Antibiotics, 2019, 8, 182.	1.5	94
23	Pharmacologically Aware Phage Therapy: Pharmacodynamic and Pharmacokinetic Obstacles to Phage Antibacterial Action in Animal and Human Bodies. Microbiology and Molecular Biology Reviews, 2019, 83, .	2.9	116
24	Commentary: A Host-Produced Quorum-Sensing Autoinducer Controls a Phage Lysis-Lysogeny Decision. Frontiers in Microbiology, 2019, 10, 1171.	1.5	15
25	Phage Therapy: Various Perspectives on How to Improve the Art. Methods in Molecular Biology, 2018, 1734, 113-127.	0.4	35
26	Basic Phage Mathematics. Methods in Molecular Biology, 2018, 1681, 3-30.	0.4	28
27	Fighting Fire with Fire: Phage Potential for the Treatment of E. coli O157 Infection. Antibiotics, 2018, 7, 101.	1.5	12
28	Bacteriophage-Mediated Biocontrol of Wound Infections, and Ecological Exploitation of Biofilms by Phages. Recent Clinical Techniques, Results, and Research in Wounds, 2018, , 121-158.	0.1	15
29	Detection of Bacteriophages: Phage Plaques. , 2018, , 1-32.		7
30	Bacteriophage Pharmacology and Immunology. , 2018, , 1-45.		2
31	Lysogeny in nature: mechanisms, impact and ecology of temperate phages. ISME Journal, 2017, 11, 1511-1520.	4.4	510
32	Information Phage Therapy Research Should Report. Pharmaceuticals, 2017, 10, 43.	1.7	70
33	Editorial: Phage Therapy: Past, Present and Future. Frontiers in Microbiology, 2017, 8, 981.	1.5	163
34	Commentary: Communication between Viruses Guides Lysis–Lysogeny Decisions. Frontiers in Microbiology, 2017, 8, 983.	1.5	30
35	Bacteriophage Clinical Use as Antibacterial "Drugs― Utility and Precedent. Microbiology Spectrum, 2017, 5, .	1.2	40
36	Phage "delay―towards enhancing bacterial escape from biofilms: a more comprehensive way of viewing resistance to bacteriophages. AIMS Microbiology, 2017, 3, 186-226.	1.0	74

STEPHEN T ABEDON

#	Article	IF	CITATIONS
37	An online phage therapy bibliography: separating under-indexed wheat from overly indexed chaff. AIMS Microbiology, 2017, 3, 525-528.	1.0	2
38	Active bacteriophage biocontrol and therapy on sub-millimeter scales towards removal of unwanted bacteria from foods and microbiomes. AIMS Microbiology, 2017, 3, 649-688.	1.0	31
39	Commentary: Phage Therapy of Staphylococcal Chronic Osteomyelitis in Experimental Animal Model. Frontiers in Microbiology, 2016, 7, 1251.	1.5	19
40	Phage therapy dosing: The problem(s) with multiplicity of infection (MOI). Bacteriophage, 2016, 6, e1220348.	1.9	107
41	Diversity of phage infection types and associated terminology: the problem with â€~Lytic or lysogenic'. FEMS Microbiology Letters, 2016, 363, fnw047.	0.7	156
42	Bacteriophage exploitation of bacterial biofilms: phage preference for less mature targets?. FEMS Microbiology Letters, 2016, 363, fnv246.	0.7	76
43	Ecology of Anti-Biofilm Agents I: Antibiotics versus Bacteriophages. Pharmaceuticals, 2015, 8, 525-558.	1.7	60
44	Ecology of Anti-Biofilm Agents II: Bacteriophage Exploitation and Biocontrol of Biofilm Bacteria. Pharmaceuticals, 2015, 8, 559-589.	1.7	81
45	Bacteriophage secondary infection. Virologica Sinica, 2015, 30, 3-10.	1.2	53
46	Phage therapy of pulmonary infections. Bacteriophage, 2015, 5, e1020260.	1.9	79
47	Re-establishing a place for phage therapy in western medicine. Future Microbiology, 2015, 10, 685-688.	1.0	111
48	Virus ecology and disturbances: impact of environmental disruption on the viruses of microorganisms. Frontiers in Microbiology, 2014, 5, 700.	1.5	6
49	Phage Therapy: Eco-Physiological Pharmacology. Scientifica, 2014, 2014, 1-29.	0.6	40
50	Bacteriophages and their Enzymes in Biofilm Control. Current Pharmaceutical Design, 2014, 21, 85-99.	0.9	160
51	Phage cocktails and the future of phage therapy. Future Microbiology, 2013, 8, 769-783.	1.0	692
52	Are archaeons incapable of being parasites or have we simply failed to notice?. BioEssays, 2013, 35, 501-501.	1.2	3
53	Archaeal Viruses, Not Archaeal Phages: An Archaeological Dig. Archaea, 2013, 2013, 1-10.	2.3	16
54	Thinking about microcolonies as phage targets. Bacteriophage, 2012, 2, 200-204.	1.9	22

STEPHEN T ABEDON

#	Article	IF	CITATIONS
55	Smaller Fleas: Viruses of Microorganisms. Scientifica, 2012, 2012, 1-23.	0.6	32
56	Bacterial â€~immunity' against bacteriophages. Bacteriophage, 2012, 2, 50-54.	1.9	78
57	Phage Therapy Pharmacology. Advances in Applied Microbiology, 2012, 78, 1-23.	1.3	156
58	Salutary Contributions of Viruses to Medicine and Public Health. , 2012, , 389-405.		1
59	Spatial Vulnerability: Bacterial Arrangements, Microcolonies, and Biofilms as Responses to Low Rather than High Phage Densities. Viruses, 2012, 4, 663-687.	1.5	68
60	Lysis from without. Bacteriophage, 2011, 1, 46-49.	1.9	293
61	Envisaging bacteria as phage targets. Bacteriophage, 2011, 1, 228-230.	1.9	20
62	Facilitation of CRISPR adaptation. Bacteriophage, 2011, 1, 179-181.	1.9	11
63	Phage treatment of human infections. Bacteriophage, 2011, 1, 66-85.	1.9	734
64	Bacteriophage prehistory. Bacteriophage, 2011, 1, 174-178.	1.9	77
65	Pros and cons of phage therapy. Bacteriophage, 2011, 1, 111-114.	1.9	691
66	Communication Among Phages, Bacteria, and Soil Environments. Soil Biology, 2011, , 37-65.	0.6	14
67	Phage Therapy Pharmacology. Current Pharmaceutical Biotechnology, 2010, 11, 28-47.	0.9	214
68	Phage Therapy in Clinical Practice: Treatment of Human Infections. Current Pharmaceutical Biotechnology, 2010, 11, 69-86.	0.9	550
69	Bacteriophage Host Range and Bacterial Resistance. Advances in Applied Microbiology, 2010, 70, 217-248.	1.3	572
70	Chapter 1 Phage Evolution and Ecology. Advances in Applied Microbiology, 2009, 67, 1-45.	1.3	103
71	Bacteriophage Plaques: Theory and Analysis. Methods in Molecular Biology, 2009, 501, 161-174.	0.4	92
72	Kinetics of Phage-Mediated Biocontrol of Bacteria. Foodborne Pathogens and Disease, 2009, 6, 807-815.	0.8	107

2

#	Article	IF	CITATIONS
73	Phages, ecology, evolution. , 2008, , 1-28.		15
74	Impact of spatial structure on phage population growth. , 2008, , 94-113.		7
75	Phages, bacteria, and food. , 2008, , 302-331.		10
76	Phage ecology of bacterial pathogenesis. , 2008, , 353-386.		8
77	Bacteriophage evolution given spatial constraint. Journal of Theoretical Biology, 2007, 248, 111-119.	0.8	46
78	Optimizing bacteriophage plaque fecundity. Journal of Theoretical Biology, 2007, 249, 582-592.	0.8	62
79	Why bacteriophage encode exotoxins and other virulence factors. Evolutionary Bioinformatics, 2007, 1, 97-110.	0.6	40
80	Why Bacteriophage Encode Exotoxins and other Virulence Factors. Evolutionary Bioinformatics, 2005, 1, 117693430500100.	0.6	46
81	Experimental Examination of BacteriophageLatent-Period Evolution as a Response to BacterialAvailability. Applied and Environmental Microbiology, 2003, 69, 7499-7506.	1.4	136
82	Bacteriophage Latent-Period Evolution as a Response to Resource Availability. Applied and Environmental Microbiology, 2001, 67, 4233-4241.	1.4	211
83	The Murky Origin of Snow White and Her T-Even Dwarfs. Genetics, 2000, 155, 481-486.	1.2	45
84	Bacteriophage T4 resistance to lysis-inhibition collapse. Genetical Research, 1999, 74, 1-11.	0.3	45
85	The Roles of the Bacteriophage T4 r Genes in Lysis Inhibition and Fine-Structure Genetics: A New Perspective. Genetics, 1998, 148, 1539-1550.	1.2	85
86	Selection for lysis inhibition in bacteriophage. Journal of Theoretical Biology, 1990, 146, 501-511.	0.8	67
87	Phage population growth: constraints, games, adaptation. , 0, , 64-93.		14
88	Modeling bacteriophage population growth. , 0, , 389-414.		11
89	Modeling phage plaque growth. , 0, , 415-438.		9

90 Bacteriophage Clinical Use as Antibacterial "Drugs― Utility and Precedent. , 0, , 417-451.

#	Article	IF	CITATIONS
91	Phage Ecology and Bacterial Pathogenesis. , 0, , 66-91.		9